Predicting Neutropenia Factors in Solid Malignancies Patients Received Chemotherapy
Article Sidebar
Main Article Content
Abstract
Background: Febrile Neutropenia is a serious complication of chemotherapy in solid malignancies and haematologic malignancies. Exploring of predicting factors for neutropenia, may be one of the indicators for appropriate chemotherapy administration and reducing febrile neutropenia.
Objective: To study predicting neutropenia factors in solid malignancies patients received chemotherapy.
Methods: A retrospective matched case-control study was performed in oncology unit, Buri Ram Hospital between 1th March 2013 and 30th November 2021. There were 407 solid malignancies patients who received the same regimens and cycles of chemotherapy met inclusion criteria for statistical analysis. Analysis with Multivariable binary logistic regression with cluster robusts.
Results: According to 204 neutropenia and 203 non-neutropenia patients, the common toxicity criteria for adverse event (CTCAE) v4.0 were significant predicting neutropenia factors (p-value < 0.021)
Conclusion: This study may suggest for chemotherapy dose reduction or delaying chemotherapy in solid malignancies patients who have history of CTCAE v4.0 during chemotherapy.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Yapici O, Gunseren F, Yapici H, Merdin A, Yaylali ÜÜ, Merdin FA. Evaluation of febrile neutropenic episodes in adult patients with solid tumors. Mol Clin Oncol 2016;4(3):379-82. doi: 10.3892/mco.2015.722.
Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106(10):2258-66. doi: 10.1002/cncr.21847.
Pathak R, Giri S, Aryal MR, Karmacharya P, Bhatt VR, Martin MG. Mortality, length of stay, and health care costs of febrile neutropenia-related hospitalizations among patients with breast cancer in the United States. Support Care Cancer 2015;23(3):615-7. doi: 10.1007/s00520-014-2553-0.
Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18(16):3038-51. doi: 10.1200/JCO.2000.18.16.3038.
Clark OA, Lyman G, Castro AA, Clark LG, Djulbegovic B. Colony stimulating factors for chemotherapy induced febrile neutropenia. Cochrane Database Syst Rev 2003;(3):CD003039. doi: 10.1002/14651858.CD003039.
Dulisse B, Li X, Gayle JA, Barron RL, Ernst FR, Rothman KJ, et al. A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia. J Med Econ 2013;16(6):720-35. doi: 10.3111/13696998.2013.782034.
Moreira-Pinto J, Leão I, Palmela C, Branco F, Godinho J, Simões P, et al. Febrile Neutropenia in Patients with Solid Tumors Undergoing Intravenous Chemotherapy. Oncol Res Treat 2020;43(11):605-12. doi: 10.1159/000506109.
Aagaard T, Reekie J, Jørgensen M, Roen A, Daugaard G, Specht L, et al. Mortality and admission to intensive care units after febrile neutropenia in patients with cancer. Cancer Med 2020;9(9):3033-42. doi: 10.1002/cam4.2955.
Hashiguchi Y, Kasai M, Fukuda T, Ichimura T, Yasui T, Sumi T. Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy. Anticancer Drugs 2015;26(10):1054-60. doi: 10.1097/CAD.0000000000000279.
Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004 Jan 15;100(2):228-37. doi: 10.1002/cncr.11882.
Dale DC, Crawford J, Lyman G. Chemotherapy-induced neutropenia and associated complications in randomized clinical trials: an evidence-based review [abstract 1638].Proc Am Soc Clin Oncol 2001;20:410a.
Gómez H, Hidalgo M, Casanova L, Colomer R, Pen DL, Otero J, Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis. J Clin Oncol 1998;16(6):2065-9. doi: 10.1200/JCO.1998.16.6.2065.
Mitsuru Muto, Tatsuru Kaji, Shun Onishi, Keisuke Yano, Waka Yamada, Satoshi Ieiri. An overview of the current management of short-bowel syndrome in pediatric patients. Surgery Today 2022;52:12–21.
Grebeldinger S, Marinković S. [Short bowel syndrome--surgical aspects]. [Article in Croatian]. Med Pregl 1998;51(9-10):405-9.
Cesaire M, Le Mauff B, Rambeau A, Toutirais O, Thariat J. [Mechanisms of radiation-induced lymphopenia and therapeutic impact]. Bull Cancer 2020;107(7-8):813-22. doi: 10.1016/j.bulcan.2020.04.009.
Iorio GC, Spieler BO, Ricardi U, Dal Pra A. The Impact of Pelvic Nodal Radiotherapy on Hematologic Toxicity: A Systematic Review with Focus on Leukopenia, Lymphopenia and Future Perspectives in Prostate Cancer Treatment. Crit Rev Oncol Hematol 2021;168:103497. doi: 10.1016/j.critrevonc.2021.103497.
Flores IQ, Ershler W. Managing neutropenia in older patients with cancer receiving chemotherapy in a community setting. Clin J Oncol Nurs 2010;14(1):81-6. doi: 10.1188/10.CJON.81-86.
